SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019 - 2018 - 2017 - 2016

August 2018 Scleroderma News

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis. Corbus Pharmaceuticals announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis. Globe Newswire, 07/25/2018. (Also see Treatments for Dermatomyositis, Endocannabinoid System and Clinical Trials)

Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. This was a small single center study and the role of tranilast in the management in scleroderma warrants further investigation in larger trials. Dove Press, 07/04/2018. (Also see Clinical Trials and Morphea Treatments)

Prediction of progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc): the SPAR model. The evidence–based SPAR prediction model developed in our study might be helpful for the risk stratification of patients with mild SSc–ILD in clinical practice and cohort enrichment for future clinical trial design. PubMed, Ann Rheum Dis, 06/06/2018. (Also see Severity and Prognosis for Scleroderma Pulmonary Involvement)

Ophthalmic findings in linear scleroderma manifesting as facial en coup de sabre. In addition to the established feature of enophthalmos, the oculometric evidence suggested smaller eye and rectus muscle involvement, interpreted as a secondary negative trophic effect of the overlying skin disorder on eye structures. PubMed, Eye (Lond), 07/04/2018. (Also see En Coup de Sabre)

Association of serum homocysteine level and lung involvement in systemic sclerosis (SSc). It seems that the serum level of homocystein has a minor role in the lung involvement of SSc patients or its effects are modified by other factors. PubMed, Curr Rheumatol Rev, 06/28/2018. (Also see Pulmonary Fibrosis Disease Correlations)

Adipocyte–specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis Our results implicate, for the first time, to our knowledge, deregulated NCoR/PPAR-γ pathways in SSc, and they support a role of adipocyte modulation of skin fibrosis. BMC, Arthritis Research & Therapy, 07/11/2018. (Also see Skin Fibrosis)

Case Report: Bladder Malakoplakia in Systemic Sclerosis Patient. This is the first case report of malakoplakia in a systemic sclerosis patient. PubMed, J Endourol Case Rep. (Also see Interstitial Cystitis)

Treatment of small intestinal bacterial overgrowth (SIBO) in systemic sclerosis (SSc): a systematic review. For some SSc patients, antibiotics can eradicate SIBO and there is a paucity of data reporting the effectiveness of either prokinetics or probiotics in SSc. PubMed, Rheumatology (Oxford), 07/02/2018. (Also see Bowel Dysfunction)

B cell activating factor (BAFF) inhibition attenuates fibrosis in scleroderma (SSc) by modulating the regulatory and effector B cell balance. BAFF inhibition is a potential therapeutic strategy for SSc via alteration of B cell balance. Science Advances, 07/11/2018. (Also see B Cells and T Cells)

Researchers find compound that may halt some fibrotic diseases. Researchers have discovered why scar tissues in some fibrotic diseases strangle vital organs, and may have identified the trigger and a method of treatment. UPI Health News, 07/12/2018. (Also see Pulmonary Fibrosis Treatments)

Go to Scleroderma Medical News: July 2018
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!